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Abstract
Based on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also
called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth fac-
tor-beta family, and Matrix Metalloproteinase-9 (MMP9), a member of the matrix metallopro-
tease family may be potential markers for Lewy body disorders, i.e. Parkinson’s disease
with (PDD) and without dementia (PDND) and Lewy body dementia (DLB). GDF15 has a
prominent role in development, cell proliferation, differentiation, and repair, whereas MMP9
degrades, as a proteolytic enzyme, components of the extracellular matrix. In this study,
cerebrospinal fluid GDF15 and MMP9 levels of 59 PDND, 17 PDD and 23 DLB patients, as
well as of 95 controls were determined, and associated with demographic, clinical and bio-
chemical parameters. Our analysis confirmed the already described association of GDF15
levels with age and gender. Corrected GDF15 levels were significantly higher in PDD than
in PDND patients, and intermediate in DLB patients. Within Lewy body disorders, GDF15
levels correlated positively with age at onset of Parkinsonism and dementia, Hoehn & Yahr
stage and cerebrospinal fluid t-Tau and p-Tau levels, and negatively with the Mini Mental
State Examination. Remarkably, it does not relevantly correlate with disease duration.
MMP9 was not relevantly associated with any of these parameters. Cerebrospinal GDF15,
but not MMP9, may be a potential marker of and in Lewy body disorders.
Introduction
At present, there is no biomarker in blood or cerebrospinal fluid (CSF) available that can differ-
entiate between Lewy body disorders and controls with sufficient accuracy, not to mention the
capability of such markers to predict the disease, or correlate with disease progression [1].
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Growth/Differentiation Factor-15 (GDF15, identical to Macrophage Inhibitory Cytokine-1,
MIC1) [2] and Matrix Metalloproteinase-9 (MMP9) belong to the Transforming growth fac-
tor-beta (TGF-beta) superfamily. Members of this family have prominent roles in develop-
ment, cell proliferation, differentiation, and repair [3]. GDF15 is widely expressed in the
central nervous system (CNS) and peripheral nervous system, most prominent in the choroid
plexus, and secreted into the cerebrospinal fluid (CSF) [3]. The protein is up-regulated as part
of the anti-inflammatory cytokine network within the CNS in response to injury and lesions
[4,5], supplementing the roles of other members of the TGF-beta superfamily [6]. Moreover,
GDF15 serves as an autocrine regulatory molecule in monocytoid cells, where expression of the
protein may be required to limit or inhibit macrophage activation at a later phase [7]. Interest-
ingly, GDF15 has been shown to act as a potent trophic and protective factor for dopaminergic
neurons: According to recent results [3], GDF15 seems to be at least as potent as glial derived
neurotrophic factor in promoting the survival of dopaminergic neurons, and normalizes motor
behaviour. It also protects dopaminergic neurons against iron intoxication [8], induces neuro-
nal survival by activating protein kinase B and glycogen synthase kinase via phosphatidylinosi-
tol 3 kinase, and attenuates formation of reactive oxidative species [9]. GDF15 probably acts
directly on neurons [3]. Remarkably, GDF15 levels have been associated with cognitive perfor-
mance and decline. Higher GDF15 levels were shown to be significantly associated with lower
global cognition in a cohort of more than 1000 non-demented adults aged 70–90 years [10].
MMP9 is a stress response cytokine [11]. It is capable of degrading stable compounds of the
extracellular matrix, as well as growth factors, cytokines, chemokines, cell surface receptors,
and serine proteases inhibitors [12–15]. MMP9 is released from astrocytes, neurons and micro-
glia as well as leukocytes and macrophages as an inactive proprotein, which is then activated by
extracellular proteinases. MMP9 has been shown to be a potential biomarker for outcome pre-
diction after neuron damage [14], and is particularly induced in neuronal lesions and cerebral
ischemia [16]. Moreover, MMP9 might be important in remyelination processes as it facilitates
oligodendrocyte regrowth [17]. MMP9 has been found to co-localize with neurofibrillary tan-
gles, senile plaques and the vascular wall in post-mortem Alzheimer brains [18,19]. MMP9
synthesis is e.g. induced by Abeta1-42 peptide [20,21], and vice versa, MMP9 is capable of
degrading Abeta1-42 [22].
Based on this knowledge about GDF15 and MMP9 in acute and chronic brain conditions
with and without dopaminergic loss and neurodegeneration, we set out to measure CSF levels
of these two proteins in a large cohort of Lewy body disorders, i.e. Parkinson’s disease without
(PD no dementia, PDND), PD with dementia (PDD) and dementia with Lewy bodies (DLB),
to determine their associations with demographical, clinical and routine CSF parameters.
Methods
Ethics Statement
The study was approved by the ethics committee of the Medical Faculty, University of Tuebin-
gen (Germany), and was performed in accordance with the Declaration of Helsinki. All partici-
pants, or their next of kin in the case of cognitive impairment (MMSE score of 18 or below),
provided their informed written consent.
Study Participants
The study cohort consisted of 200 participants, i.e. 100 control persons and 100 patients with a
Lewy body disorder. All samples were collected from donors who were either patients or study
participants at the ward and outpatient clinic of the Neurodegenerative Department of the Uni-
versity of Tuebingen, Germany. From all included donors, information about gender, age, age
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at onset of Parkinsonism, age at onset of dementia, disease duration, Hoehn and Yahr scale
(H&Y), Mini Mental State Examination (MMSE) scores and information about medication
were collected. Diagnoses of PDND, PDD and DLB as well as of controls (exclusion of a neuro-
logical disease according to medical history and clinical examination) were made by movement
disorders specialists according to established criteria [23–25]. One PDND patient and five con-
trols were excluded from the final analysis due to missing data (neurodegenerative markers or
MMP9 values not available), resulting in data available for final analysis of 99 patients with a
Lewy body disorder (59 PDND, 17 PDD, and 23 DLB patients) and 95 controls. Excluded indi-
viduals did not relevantly differ from those included with regard to demographic and clinical
data. Details are provided in Table 1.
Cerebrospinal Fluid and Serum Collection
CSF and serum collection was performed according to standardized protocols (for details see
[26]). In brief, serum and CSF were centrifuged (blood: 2000 g, 4°C, 10 min; CSF: 4000 g, 4°C,
10 min) and stored at -80°C within 60 minutes after collection until analysis. Only samples
with normal routine CSF diagnostics were included (leukocytes< 4x106; IgG index CSF/
serum< 0.6, CSF albumin levels< 450 mg/l). Erythrocytes counts in CSF were performed
using a semi-quantitative approach (level 1, 0–5 erythrocytes/μL; level 2,>5–1000 erythro-
cytes/μL; level 3,>1000–5000 erythrocytes/μL). As this is a hypothesis-generating study,
Table 1. Demographical, clinical and biochemical data of the included cohorts.
PDND PDD DLB Controls p-value
Individuals (f/m) [N] 59 (30/29) 17 (8/9) 23 (12/11) 95 (55/40) 0.76
Age [y] 67 (44–79) 75 (61–84)§ 69 (50–82) 61 (38–79)§#$ <0.0001
Aao Parkinsonism [y] 62 (30–76) 62 (51–74) 67 (49–78)§ - 0.07
Duration of Parkinsonism [y] 4.0 (0.5–21.0) 10.0 (3.0–21.0)§ 2 (0.5–13.0)§# - <0.0001
H&Y stage (1–5) 2 (1–4) 3 (2–4)§ 2 (1–4)# - 0.004
H&Y stage (1/2/3/4) [N] 9/40/7/3 0/7/6/4 5/8/8/2 - 0.0054
Aao dementia [y] - 72 (58–79) 68 (49–79)# - 0.04
Duration of dementia [y] - 3.0 (0.2–5.0) 2 (0.5–12.0) - 0.67
MMSE (0–30) 29 (23–30) 23 (14–26)§ 20 (10–30)§ 30 (25–30)§#$ <0.0001
LEDD [mg L-Dopa/day] 225 (0–1333) 600 (0–1016)§ 150 (0–700)# - <0.0001
CSF Albumin [mg/L] 221 (127–391) 252 (109–440) 209 (96–427) 232 (83–575) 0.98
CSF Abeta1-42 [pg/mL] 678 (270–1458) 478 (213–771)
§ 530 (252–1241)§ 825 (318–1446)§#$ 0.00091
CSF t-Tau [pg/mL] 176 (25–710) 225 (68–660) 279 (77–596)§ 165 (32–481)$ 0.151
CSF p-Tau [pg/mL] 36 (14–111) 54 (12–109)§ 50 (26–86)§ 36 (13–76)#$ 0.0461
CSF GDF15 [pg/mL] All 200 (67–467) 292 (139–571)§ 235 (101–453)# 184 (39–461)# 0.051
f 198 (67–467) 285 (139–473) 209 (101–356)# 169 (39–371) 0.131
m 202 (113–429) 296 (204–571)§ 246 (185–453) 215 (78–461) 0.071
CSF MMP9 [pg/mL] 50 (15–283) 47 (23–176) 42 (9–133) 46 (11–439) 0.401
Aao, Age at onset; Abeta1-42, amyloid-beta1-42; CSF, cerebrospinal ﬂuid; DLB, dementia with Lewy bodies; GDF15, growth/differentiation factor 15; f,
female; H&Y, Hoehn & Yahr stage; LEDD, Levodopa equivalent daily dose; m, male; MMP9, matrixmetalloproteinase 9; MMSE, Mini Mental State
Examination; PDD, Parkinson`s disease demented; PDND, Parkinson`s disease non-demented; p-Tau, phospho-Tau; t-Tau, total Tau.
1 age-corrected p-values
§ versus PDND
# versus PDD
$ versus DLB.
doi:10.1371/journal.pone.0149349.t001
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GDF15 and MMP9 levels were only analysed in CSF. Serum was used for determination of rou-
tine laboratory measures, such as the IgG index.
Preparation of GDF15 and MMP9 Antibody-Coupled Microspheres
106 microspheres (Luminex cat L100-C104-16 for GDF15 and cat L100-C156-16 for MMP9)
were activated for 20 min in 80 μL 1.38% NaH2PO4H2O, pH 6.0 supplemented with 10 μL
sulfo-NHS (Thermo Fisher, Darmstadt, Germany). Activated microspheres were washed with
coupling buffer (1%MES, pH 5.0) by briefly vortexing and centrifugation. 200 μL of monoclo-
nal antibody MAB957 (R&D Systems, Minneapolis, USA; 250 μg IgG/mL in 1%MES, pH 5.0)
or 200 μL of monoclonal antibody MAB13458 (Millipore, Darmstadt, Germany; 250 μg IgG/
mL in 1%MES, pH 5.0) were added to the microspheres and left to react overnight at room
temperature in the dark. The coupled microspheres were centrifuged and washed two times
with PBS, 0.05% Tween-20. Microspheres were then resuspended in 500 μL PBS, 0.1% BSA,
0.05% proclin300 and stored at 4°C in the dark until use.
GDF15 Assay
3000 GDF15 antibody coupled beads (diluted into PBS, 0.1% BSA, 0.05% proclin300) were
added per well of a prewetted MultiScreen™HTS filter plate (Millipore). Wells were then
drained using a vacuum manifold holder. 25 μL assay buffer (PBS + 0.1% casein + 0.08%
CHAPS + 0.25% octylglucopyranoside [OGP]) and either 75 μL of GDF15 standard in assay
buffer (recombinant human GDF15; R&D Systems, cat# 957-GD) or CSF diluted in assay
buffer were added and incubated overnight at room temperature on a mini orbital shaker.
Wells were drained and washed 3 times with 225 μL wash buffer (PBS, 0.05% Tween-20). A
mix of 75 μL assay buffer and 25 μL biotinylated goat anti-GDF15 antibody (R&D Systems,
cat# BAF940; 5 ng/well, diluted in assay buffer) was then added and incubated for three h at
room temperature on a mini orbital shaker. The filter plate was drained and washed three
times with 225 μL wash buffer. 100 μL streptavidin R-Phycoerythrin conjugate (SA-PE)
(Thermo Fisher, cat# SA1004-1, lot# 495462A; diluted 1/300 in assay buffer) were added and
incubated for one h at room temperature on a mini orbital shaker. Filter plates were then
drained and washed three times with 225 μL wash buffer. Finally 100 μL PBS was added per
well and incubated for 10 min at room temperature on a mini orbital shaker. The median fluo-
rescent intensity (mfi) in region #104 was then determined for each well within one h using the
Luminex 100TM IS System (Luminex Corp, Austin, Texas, USA). Each filter plate contained (i)
A duplicate GDF15 standard calibrator curve (10000; 3333.33; 1111.11; 370.37; 123.46; 41.15;
13.72; 4.57; 1.52; 0.51 and 0.17 pg/mL) in assay buffer. A stock of frozen aliquots of the differ-
ent standard dilutions was used for all measurements; (ii) Two serial dilutions (1/15 and 1/60)
of each CSF sample that were prepared in assay buffer prior to analysis. Each dilution was mea-
sured in duplicate. Results obtained for the 1/15 and 1/60 dilutions showed very high concor-
dance, so only results of the 1/60 dilution experiments are presented. Results of the 1/15
dilution experiments are provided upon request; and (iii) Blank (assay buffer) in duplicate (for
further information see S1 File).
MMP9 Assay
3000 MMP9 antibody coupled beads (diluted in PBS, 0.1% casein) were added per well of a pre-
wetted MultiScreen™HTS filter plate (Millipore). Wells were then drained using a vacuum
manifold holder. 25 μL assay buffer (PBS + 0.1% casein + 0.08% CHAPS + 3% Pluronic F-127)
and 75 μL of MMP9 standard in assay buffer (recombinant human MMP9; R&D Systems, cat#
911-MP) or CSF diluted in assay buffer were added and incubated overnight at room
GDF-15 and MMP-9 in LBD
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temperature on a mini orbital shaker. Wells were drained and washed 3 times with 225 μL
wash buffer. A mix of 75 μL assay buffer and 25 μL biotinylated goat anti-MMP9 antibody
(R&D Systems, cat# BAF911; 50 ng/well, diluted in assay buffer) was then added and incubated
for three h at room temperature on a mini orbital shaker. The filter plate was drained and
washed three times with 225 μL wash buffer (PBS, 0.05% Tween-20). 100 μL SA-PE conjugate
(Thermo Fisher, cat# SA1004-1, lot# 495462A; diluted 1/300 in assay buffer) were added and
incubated for one h at room temperature on a mini orbital shaker. Filter plates were then
drained and washed three times with 225 μL wash buffer. Finally 100 μL PBS was added per
well and incubated for 10 min at room temperature on a mini orbital shaker. The mfi in region
#156 was then determined for each well within one h using the Luminex 100TM IS System.
Each plate contained (i) A duplicate MMP9 standard calibrator curve (30,000; 7,500; 1,875;
468.75; 117.19; 29.3; 7.32; 1.83; 0.45; 0.11 and 0.029 pg/mL) in assay buffer. A stock of frozen
aliquots of the different standard dilutions was used for all measurements; (ii) Each CSF sample
diluted 1/24 in assay buffer and measured in quadruplate; and (iii) Blank (assay buffer) in
duplicate (for further information see S1 File).
Data Processing
Concentrations of the CSF samples were calculated using the StatLIA1 v3.2 statistical package
(Brendan Technologies Inc., Carlsbad, California, USA) using a 4 (GDF15) or 5 (MMP9)
parameter logistic curve with POM (power of mean) weighting.
Neurodegenerative Marker Analysis
Neurodegenerative markers (CSF Abeta1-42, total Tau and phospho-Tau) were determined
using Innotest1 ELISA kits #80324, #80323, or #80317, respectively (Fujirebio Germany
GmbH, Hannover, Germany).
Data Analysis
Data were analysed with JMP software (Version 11.2.0; SAS Institute Inc., Cary, North Caro-
lina, USA). Demographic and clinical data are presented with median and range / confidence
interval (CI). Comparison of GDF15 or MMP9 levels with clinical and routine biochemical
parameters were performed using Pearson correlation. Based on results of previous studies
(e.g. [27–29]) and on correlations performed in this study indicating at least a weak association
of age with GDF15, MMP9, CSF Abeta1-42, t-Tau and p-Tau, all calculations including one of
these parameters were corrected for age with a logistic regression model. Median GDF15 levels
in controls were 16.0% lower for females as compared to males (p = 0.03), therefore GDF15
was calculated separately for females and males. We also checked for potentially relevant differ-
ences of CSF albumin levels and erythrocytes/μL CSF between controls and patients with a
Lewy body disorder, which was not the case (p = 0.87 and p = 0.70, respectively). As these vari-
ables did not show relevant differences between cohorts, we did not include them as covariables
in our analyses. Due to the exploratory nature of the study, differences were considered signifi-
cant at uncorrected p< 0.05.
Results
Patients with a Lewy body disorder had higher CSF GDF15 levels, compared to controls (235
versus 184 pg/mL, p< 0.0001). Among patients, age- and gender-corrected median CSF
GDF15 levels in the PDD subgroup were 18% higher than in the DLB subgroup (95% CI
6–24%), 16% higher than in the PDND subgroup (6–27%), and 17% higher than the control
GDF-15 and MMP-9 in LBD
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group (7–28%). In the overall Lewy body disorder cohort, GDF15 was positively correlated
with age at onset of Parkinsonism, age at onset of dementia, H&Y stage, and with the neurode-
generative markers t-Tau and p-Tau. CSF GDF15 was negatively associated with the MMSE
score (Fig 1). It was not significantly associated with any other parameter comprised in the
analysis, including disease duration of Parkinsonism (r2 = 0.03, p = 0.11) and levodopa equiva-
lent daily dose (LEDD, r2 = 0.02, p = 0.19; Tables 1 and 2).
CSF MMP9 was not significantly associated with any of the included demographic, clinical
and routine neurochemical parameters. CSF GDF15 and MMP9 levels did not relevantly corre-
late. Detailed results structured by included subcohorts are shown in Table 2.
Discussion
The results of this study indicate that CSF GDF15 but not MMP9 has potential to (i) differenti-
ate Lewy body disorder patients from controls, (ii) show severity of the disease independent of
disease duration, and (iii) even detect prodromal phases of the disorder. Specifically the rela-
tively close associations of GDF15 with t-Tau and p-Tau levels are remarkable. T-Tau is associ-
ated with neuronal damage and death [30], and p-Tau with axonal pathology [31]. Both
processes [32] as well as alpha-synuclein pathology in general [33,34] have been repeatedly
associated with inflammation and remodelling, which makes it suggestive that GDF15 is
indeed involved in dopaminergic cell death and Lewy body pathology, not only in animal mod-
els (e.g. [3,35–38]) but also in humans.
CSF GDF15 levels were comparably low in controls and PDND patients (who had a relatively
short disease duration of 4.5 years, mild motor signs and good cognitive function), intermediate
in DLB patients (who had relatively good motor, but poor cognitive functioning), and highest in
PDD patients (who had most regularly poor motor and poor cognitive functions). Consistent
with this observation, disease severity parameters (H&Y andMMSE) were accordingly correlated
Fig 1. Significant correlations of cerebrospinal fluid GDF15 levels with clinical and routine neurodegenerativemarkers in Lewy body disorders. (A)
GDF15 and age of onset of Parkinsonism. (B) GDF15 and age of onset of dementia. (C) GDF15 and Hoehn and Yahr score. (D) GDF15 and t-Tau. (E)
GDF15 and p-Tau. (F) GDF15 and Mini Mental State Examination. Aao, age at onset; CSF, cerebrospinal fluid; GDF15, growth differentiation factor 15; H&Y,
Hoehn and Yahr score; MMSE, Mini Mental State Examination; p-Tau, phospho-Tau; r2, correlation coefficient; t-Tau, total-Tau.
doi:10.1371/journal.pone.0149349.g001
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Table 2. Correlation coefficients (r2) of CSF GDF15 and MMP9 and demographic, clinical and neurodegenerative parameters.
PDND PDD DLB Controls
GDF15 All Gender 0.00 0.07 0.29** 0.08**
Age 0.36*** 0.38** 0.15 0.45***
Aao Parkinsonism 0.29*** 0.19 0.16 -
Duration of Parkinsonism 0.00 0.06 0.00 -
H&Y stage 0.06 0.38** 0.00 -
Aao dementia - 0.30* 0.13 -
Duration of dementia - 0.21 0.00 -
MMSE 0.01 0.26* 0.00 0.01
LEDD 0.07* 0.18 0.03 -
CSF Abeta1-42 0.04
1 0.011 0.291* 0.081
CSF t-Tau 0.491*** 0.121 0.301 0.041
CSF p-Tau 0.431*** 0.081 0.191 0.011
f Age 0.39*** 0.61* 0.34* 0.49***
Aao Parkinsonism 0.40*** 0.47 0.30 -
Duration of Parkinsonism 0.09 0.04 0.01 -
H&Y stage total 0.03 0.23 0.04 -
Aao dementia - 0.51* 0.37* -
Duration of dementia - 0.75** 0.02 -
MMSE 0.01 0.26 0.23 0.00
LEDD 0.11 0.34 0.07 -
CSF Abeta1-42 0.17
1 0.921** 0.101 0.171
CSF t-Tau 0.681*** 0.051 0.401 0.091
CSF p-Tau 0.741*** 0.011 0.191 0.101
m Age 0.33** 0.32 0.23 0.45***
Aao Parkinsonism 0.19* 0.12 0.20 -
Duration of Parkinsonism 0.12 0.08 0.02 -
H&Y stage total 0.13 0.44 0.01 -
Aao dementia - 0.24 0.16 -
Duration of dementia - 0.06 0.00 -
MMSE 0.05 0.20 0.13 0.06
LEDD 0.04 0.09 0.00 -
CSF Abeta1-42 0.01
1 0.021 0.481 0.031
CSF t-Tau 0.351* 0.621 0.411 0.021
CSF p-Tau 0.201 0.451 0.461 0.001
MMP9 Gender 0.00 0.05 0.08 0.01
Age 0.02 0.01 0.07 0.01
Aao Parkinsonism 0.00 0.05 0.05 -
Duration of Parkinsonis 0.01 0.04 0.01 -
H&Y stage total 0.02 0.00 0.07 -
Aao dementia - 0.01 0.05 -
Duration of dementia - 0.04 0.02 -
MMSE 0.00 0.00 0.06 0.00
LEDD 0.02 0.11 0.00 -
CSF Abeta1-42 0.00
1 0.001 0.011 0.091
CSF t-Tau 0.101 0.161 0.211 0.021
(Continued)
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with GDF15 levels. Hence, comparable to Tau levels, GDF15 levels seem to be directly associated
with severity and co-occurrence of symptoms in Lewy body disorders, rather than with specific
subtypes and with “simple” disease duration. This observation is, indirectly and outside the Lewy
body field, confirmed by studies with initially healthy older adults and patients with brain
tumours, which found higher levels of GDF15 associated with increased decline in global cogni-
tion, executive function, memory, and processing speed, and increased mortality [10,39].
Although this is a cross-sectional analysis, our results suggest that CSF GDF15 levels have
even a potential to detect prodromal stages of Lewy body disorders. In our study, GDF15 levels
were higher in control males than in females. If we assume that higher levels indicate more dis-
ease “activity”, GDF15 may serve as a surrogate marker for Lewy body disorder even in prodro-
mal disease stages, as risk for Lewy body disorders is higher in males than in females [40].
Interestingly, a recent study [41] observed higher baseline levels of biomarkers indicative of
inflammation and remodelling in males compared to females, suggesting higher biological
activity in these pathophysiological pathways in males compared to females. Moreover, GDF15
levels were positively and closely correlated with age at onset of Parkinsonism and dementia.
In other words, the higher the CSF GDF15 levels, the later occurred the disease itself, and cog-
nitive deterioration within the disease which is closely associated with the disorder.
Taken together, CSF GDF15 levels show surprisingly high association values with relevant
clinical, demographic and biochemical parameters of Lewy body disorder, with negative associ-
ations with severity of symptoms. We therefore hypothesize that GDF15 as a central member
of neuroprotective mechanisms is induced by brain injury [42], such as neurodegeneration.
These mechanisms obviously include further anti-inflammatory species and neurotrophic fac-
tors. In a recent study using multiplex panels, we observed increased levels of such species and
factors (note that we could not determine GDF15 levels due to technical issues) in PD patients
compared to controls [43]. Moreover, it may well be that a subtype of PD / DLB exists that is
particularly influenced by these anti-inflammatory species and neurotrophic factors: We found
that PD patients with a LRRK2mutation who displayed a diffuse-malignant phenotype [44],
showed higher levels compared to PD LRRK2 patients with the much more benign pure motor
phenotype [45].
Use of MMP inhibitors in Parkinson’s disease might show great promise as the death of
dopaminergic neurons seems to be associated with release of MMPs by the activated cells
around them [46], making the definition of useful outcome parameters inevitable. However,
CSF MMP9 levels between patients with Lewy body disorder and controls did not differ signifi-
cantly in our analyses, indicating that this parameter does not have a high potential as trait
Table 2. (Continued)
PDND PDD DLB Controls
CSF p-Tau 0.131 0.141 0.151 0.011
Pearson correlation and a logistic regression model including age as a covariate 1 were used to calculate the extent of correlation between both, growth
differentiation factor 15 (GDF15) and matrix metalloproteinase 9 (MMP9), with demographic and clinical parameters of Lewy body disorder subcohorts.
The correlation coefﬁcient (r2) is presented. Aao, Age at onset; Abeta1-42, Amyloid-beta1-42; CSF, cerebrospinal ﬂuid; DLB, dementia with Lewy bodies; f,
female; H&Y, Hoehn & Yahr stage; LEDD, Levodopa equivalent daily dose; m, male; MMSE, Mini Mental State Examination; PDD, Parkinson`s disease
demented; PDND, Parkinson`s disease non-demented; p-Tau, phospho-Tau; t-Tau, total Tau.
* p < 0.05
** p < 0.01
*** p < 0.001.
doi:10.1371/journal.pone.0149349.t002
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marker for the disease. Moreover, none of the demographic, clinical and neurochemical mark-
ers showed significant correlations with CSF MMP9 levels, arguing against the potential of CSF
MMP9 as state and predictive marker of the disease. Therefore, even if MMP inhibitors will be
tested in Lewy body disorders, the usefulness of at least CSF MMP9 as an outcome parameter
remains unclear at present.
The study has limitations. First, we measured a cross-sectional sample, and, particularly as
the results indicate that CSF GDF15 is associated with severity of disease, longitudinal informa-
tion will be necessary to clarify the specific role of the protein with respect to prediction and
evaluation of disease severity in Lewy body disorders. Second, due to the complex collection
process, cohort sizes are relatively small, and a second study using independent samples is cer-
tainly necessary to validate our results. The strength of the study is the examination of biofluid
samples from one biobank with highly standardized and fast sample processing and storage
procedures, including only material from patients and controls evaluated by movement disor-
der specialists.
In conclusion, CSF levels of GDF15, but not MMP9, are associated with occurrence and
severity in Lewy body disorders. CSF GDF15 may therefore serve as an interesting parameter
for, e.g. a panel that aims at differentiating Lewy body disorders from controls, and for progres-
sion studies in this arena. Moreover, the direct correlation of CSF GDF15 with age at onset of
Parkinsonism and dementia as well as the gender difference of the parameter suggests that
GDF15 in CSF has some potential to detect prodromal phases of the disease.
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